Neutrophil Extracellular Trap Formation Correlates with Favorable Overall Survival in High Grade Ovarian Cancer.
eicosanoids
mass spectrometry
metabolomics
neutrophil extracellular traps
ovarian cancer
proteomics
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Feb 2020
21 Feb 2020
Historique:
received:
10
01
2020
revised:
12
02
2020
accepted:
17
02
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
27
2
2020
Statut:
epublish
Résumé
It is still a question of debate whether neutrophils, often found in the tumor microenvironment, mediate tumor-promoting or rather tumor-inhibiting activities. The present study focuses on the involvement of neutrophils in high grade serous ovarian cancer (HGSOC). Macroscopic features classify two types of peritoneal tumor spread in HGSOC. Widespread and millet sized lesions characterize the miliary type, while non-miliary metastases are larger and associated with better prognosis. Multi-omics and FACS data were generated from ascites samples. Integrated data analysis demonstrates a significant increase of neutrophil extracellular trap (NET)-associated molecules in non-miliary ascites samples. A co-association network analysis performed with the ascites data further revealed a striking correlation between NETosis-associated metabolites and several eicosanoids. The congruence of data generated from primary neutrophils with ascites analyses indicates the predominance of NADPH oxidase 2 (NOX)-independent NETosis. NETosis is associated with protein S100A8/A9 release. An increase of the S100A8/CRP abundance ratio was found to correlate with favorable survival of HGSOC patients. The analysis of additional five independent proteome studies with regard to S100A8/CRP ratios confirmed this observation. In conclusion, NET formation seems to relate with better cancer patient outcome.
Identifiants
pubmed: 32098278
pii: cancers12020505
doi: 10.3390/cancers12020505
pmc: PMC7072166
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Austrian Science Fund FWF
ID : P 28137
Pays : Austria
Références
Cancer Immunol Res. 2016 Feb;4(2):83-91
pubmed: 26839309
Blood. 2019 May 16;133(20):2178-2185
pubmed: 30898862
Cancer Cell. 2014 Jul 14;26(1):77-91
pubmed: 25026212
Diagnostics (Basel). 2019 May 18;9(2):
pubmed: 31109041
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
Anal Chem. 2017 Feb 7;89(3):1945-1954
pubmed: 28208246
Nature. 2015 Dec 17;528(7582):413-7
pubmed: 26649828
Front Immunol. 2015 Aug 07;6:402
pubmed: 26300886
Cancer Lett. 2017 Mar 1;388:158-166
pubmed: 27940126
J Immunol. 1993 Aug 15;151(4):2166-75
pubmed: 8345201
Clin Proteomics. 2017 Oct 6;14:33
pubmed: 29176937
Cancer Res. 2016 Aug 1;76(15):4311-5
pubmed: 27402078
J Clin Oncol. 2009 Jul 20;27(21):3437-44
pubmed: 19470939
Immunity. 2010 Nov 24;33(5):657-70
pubmed: 21094463
Mass Spectrom Rev. 2019 Nov 18;:
pubmed: 31737933
Int J Oncol. 2018 Oct;53(4):1580-1590
pubmed: 30066851
Oncotarget. 2016 Sep 20;7(38):61336-61354
pubmed: 27665539
Nat Rev Cancer. 2015 Feb;15(2):96-109
pubmed: 25614008
Nat Rev Cancer. 2016 Jul;16(7):447-62
pubmed: 27339708
Onco Targets Ther. 2019 Oct 21;12:8687-8699
pubmed: 31695427
Front Immunol. 2013 Apr 17;4:91
pubmed: 23616785
Clin Exp Immunol. 2019 Aug;197(2):153-160
pubmed: 30873592
Cell Host Microbe. 2012 Jul 19;12(1):109-16
pubmed: 22817992
Nat Rev Immunol. 2015 Aug;15(8):511-23
pubmed: 26139350
Immunol Rev. 2016 Sep;273(1):329-43
pubmed: 27558344
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):2817-22
pubmed: 25730848
Elife. 2017 Jun 02;6:
pubmed: 28574339
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Ann N Y Acad Sci. 1997 Dec 15;832:394-404
pubmed: 9704067
J Immunol. 2010 Dec 15;185(12):7413-25
pubmed: 21098229
J Exp Med. 2019 Jan 7;216(1):176-194
pubmed: 30567719
Cancer. 2015 Feb 15;121(4):545-55
pubmed: 25336438
J Pers Med. 2019 Feb 07;9(1):
pubmed: 30736475
Nat Rev Immunol. 2013 Mar;13(3):159-75
pubmed: 23435331
Nat Rev Cancer. 2018 Jun;18(6):359-376
pubmed: 29700396
Amino Acids. 2007 Aug;33(2):231-40
pubmed: 17396215
Front Immunol. 2019 Oct 30;10:2536
pubmed: 31736963
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
J Immunol. 2003 Mar 15;170(6):3233-42
pubmed: 12626582
J Rheumatol. 2012 Apr;39(4):728-34
pubmed: 22337236
Arthritis Res Ther. 2015 Sep 15;17:252
pubmed: 26373925
Clin Cancer Res. 2017 Apr 15;23(8):2081-2092
pubmed: 27797973
Curr Mol Med. 2016;16(1):23-32
pubmed: 26695697
Oncotarget. 2015 Jul 10;6(19):17261-75
pubmed: 25991672
JCI Insight. 2019 Mar 7;4(5):
pubmed: 30730851
Nature. 2015 Jun 18;522(7556):345-348
pubmed: 25822788
Cancer Metastasis Rev. 2007 Jun;26(2):249-60
pubmed: 17415527
Proteomics Clin Appl. 2009 Aug;3(8):947-67
pubmed: 21136998
Oncotarget. 2014 Oct 15;5(19):8853-68
pubmed: 25326682
Amino Acids. 2014 Jan;46(1):7-20
pubmed: 22810731
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493-8
pubmed: 16891410
Biochim Biophys Acta. 2015 Feb;1847(2):231-240
pubmed: 25448536
Bioinformatics. 2010 Apr 1;26(7):966-8
pubmed: 20147306
Mol Cell Proteomics. 2017 Jan;16(1):86-99
pubmed: 27879288
Nat Immunol. 2001 Jul;2(7):612-9
pubmed: 11429545
J Lipid Res. 2009 Jun;50(6):1015-38
pubmed: 19244215
Clin Cancer Res. 2019 Jul 15;25(14):4309-4319
pubmed: 30979743
Blood. 2004 Oct 15;104(8):2543-8
pubmed: 15213101
Front Oncol. 2019 Aug 06;9:639
pubmed: 31448220
PLoS One. 2017 Aug 23;12(8):e0183420
pubmed: 28832684
Clin Cancer Res. 2008 Nov 1;14(21):6735-41
pubmed: 18980965
Int J Mol Sci. 2018 Apr 17;19(4):
pubmed: 29673197
Diagnostics (Basel). 2019 Aug 01;9(3):
pubmed: 31374917
J Proteome Res. 2014 Nov 7;13(11):4773-82
pubmed: 25238572
Cell. 2018 Sep 20;175(1):159-170.e16
pubmed: 30241606
Immunotherapy. 2016 Jun;8(7):821-37
pubmed: 27349981
Cancers (Basel). 2019 May 20;11(5):
pubmed: 31137558
J Cancer. 2016 Mar 10;7(5):546-54
pubmed: 27053953
Clin Proteomics. 2018 Mar 9;15:13
pubmed: 29541007
Mol Cell Proteomics. 2016 Jun;15(6):1982-97
pubmed: 27025457
Nanoscale. 2016 Aug 7;8(29):14193-202
pubmed: 27387552
Onco Targets Ther. 2016 Sep 08;9:5567-75
pubmed: 27660475
Mol Med. 2016 Oct;22:621-631
pubmed: 27453505
Nat Rev Cancer. 2016 Sep 23;16(10):663-73
pubmed: 27658636
Nature. 2019 May;569(7758):723-728
pubmed: 31043742
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249
J Immunol. 2000 Mar 1;164(5):2769-75
pubmed: 10679119